BR0007991A - Use of the compound (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] - (3r, 5s) -3,5-dihydroxiept -6-enoic, or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods of preparing a pharmaceutical composition, reducing the levels of c-ldl and the lipid ratio of c-ldl / c-hdl, and, regimen dosage - Google Patents
Use of the compound (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] - (3r, 5s) -3,5-dihydroxiept -6-enoic, or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods of preparing a pharmaceutical composition, reducing the levels of c-ldl and the lipid ratio of c-ldl / c-hdl, and, regimen dosageInfo
- Publication number
- BR0007991A BR0007991A BR0007991-0A BR0007991A BR0007991A BR 0007991 A BR0007991 A BR 0007991A BR 0007991 A BR0007991 A BR 0007991A BR 0007991 A BR0007991 A BR 0007991A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- ldl
- amino
- methyl
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"USO DO COMPOSTO áCIDO (E)-7-[4-(4-FLUOROFENIL)-6ISOPROPIL-2-[METIL(METILSULFON IL) AMINO] PIRIMIDIN -5-IL] (3R, 5S) -3,5-DIIDROXIEPT-6-ENóICO, OU DE UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO FARMACêUTICA, MéTODOS DE PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA, DE REDUçãO DOS NìVEIS DE CLDL E DA RAZãO DE LIPìDEO DE C-LDL/ C-HDL, E, REGIME DE DOSAGEM". A invenção refere-se ao uso de dosagens ou faixas de dosagens orais particulares do composto ácido (E) -7- [4-(4-fluorofenil)-6isopropil-2- [ metil (metilsufonil) amino ] piridin-5-il] - (3R, 5 S) - 3, 5diidroxiept -6- enóico, ou de um sal farmaceuticamente aceitável do mesmo, para alterar beneficamente os níveis de lipídeo ou as razões de lipídeo em um paciente humano, que tenha necessidade do mesmo, assim como a composições farmacêuticas do referido composto, ou sais adaptados para a administração oral, que compreendem tais dosagens e a métodos de preparação dos mesmos."USE OF THE ACID COMPOUND (E) -7- [4- (4-FLUOROFENIL) -6ISOPROPIL-2- [METHYL (METHILSULFON IL) AMINO] PIRIMIDIN -5-IL] (3R, 5S) -3,5-DIIDROXIEPT- 6-OENIC, OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, PHARMACEUTICAL COMPOSITION, METHODS OF PREPARING A PHARMACEUTICAL COMPOSITION, REDUCING THE CLDL LEVELS AND THE REASON OF C-LDL / C-LIME, HD-LIME, . The invention relates to the use of particular oral dosages or dosage ranges of the acid compound (E) -7- [4- (4-fluorophenyl) -6isopropyl-2- [methyl (methylsufonyl) amino] pyridin-5-yl] - (3R, 5 S) - 3, 5diidroxiept -6- enoico, or a pharmaceutically acceptable salt thereof, to beneficially alter the lipid levels or lipid ratios in a human patient who needs it, as well as pharmaceutical compositions of said compound, or salts adapted for oral administration, comprising such dosages and methods of preparing them.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9902590.0A GB9902590D0 (en) | 1999-02-06 | 1999-02-06 | Use of cholesterol-lowering agent |
| GBGB9921062.7A GB9921062D0 (en) | 1999-09-08 | 1999-09-08 | Use of cholestrol-lowering agent |
| PCT/GB2000/000285 WO2000045819A1 (en) | 1999-02-06 | 2000-02-01 | Use of cholesterol-lowering agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0007991A true BR0007991A (en) | 2001-11-06 |
Family
ID=26315084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0007991-0A BR0007991A (en) | 1999-02-06 | 2000-02-01 | Use of the compound (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] - (3r, 5s) -3,5-dihydroxiept -6-enoic, or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods of preparing a pharmaceutical composition, reducing the levels of c-ldl and the lipid ratio of c-ldl / c-hdl, and, regimen dosage |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1150679A1 (en) |
| JP (2) | JP2002536333A (en) |
| KR (1) | KR100699287B1 (en) |
| CN (1) | CN1347320A (en) |
| AR (1) | AR022462A1 (en) |
| AU (1) | AU769897B2 (en) |
| BR (1) | BR0007991A (en) |
| CA (1) | CA2358641A1 (en) |
| CZ (1) | CZ20012631A3 (en) |
| EE (1) | EE04659B1 (en) |
| HK (1) | HK1040924A1 (en) |
| HU (1) | HUP0105019A3 (en) |
| ID (1) | ID30131A (en) |
| IL (1) | IL144662A0 (en) |
| IS (1) | IS5996A (en) |
| MY (1) | MY136382A (en) |
| NO (1) | NO319827B1 (en) |
| NZ (1) | NZ512681A (en) |
| PL (1) | PL349137A1 (en) |
| SK (1) | SK11112001A3 (en) |
| TR (1) | TR200102236T2 (en) |
| WO (1) | WO2000045819A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| SE0103509D0 (en) * | 2001-10-19 | 2001-10-19 | Astrazeneca Ab | Rosuvastatin in pre-demented states |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| WO2007142581A1 (en) * | 2006-06-07 | 2007-12-13 | Astrazeneca Ab | Combination product for the treatment or prevention of dyslipidaemia |
| WO2008156718A1 (en) * | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Cetp inhibitors derived from benzoxazole arylamides |
| JP2010530416A (en) | 2007-06-20 | 2010-09-09 | メルク・シャープ・エンド・ドーム・コーポレイション | CETP inhibitors derived from benzoxazole arylamides |
| AU2008266956A1 (en) * | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | CETP inhibitors derived from benzoxazole arylamides |
| EP2216095A1 (en) * | 2009-01-27 | 2010-08-11 | Koninklijke Philips Electronics N.V. | Microfluidic device for full blood count |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260446A (en) * | 1989-12-22 | 1993-11-09 | Basf Aktiengesellschaft | Aminothiazoles |
| JP2648897B2 (en) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | Pyrimidine derivatives |
-
2000
- 2000-01-31 AR ARP000100408A patent/AR022462A1/en unknown
- 2000-02-01 JP JP2000596939A patent/JP2002536333A/en not_active Withdrawn
- 2000-02-01 PL PL00349137A patent/PL349137A1/en not_active Application Discontinuation
- 2000-02-01 TR TR2001/02236T patent/TR200102236T2/en unknown
- 2000-02-01 KR KR1020017009822A patent/KR100699287B1/en active IP Right Review Request
- 2000-02-01 CN CN00803519A patent/CN1347320A/en active Pending
- 2000-02-01 CZ CZ20012631A patent/CZ20012631A3/en unknown
- 2000-02-01 IL IL14466200A patent/IL144662A0/en unknown
- 2000-02-01 EE EEP200100404A patent/EE04659B1/en not_active IP Right Cessation
- 2000-02-01 ID IDW00200101666A patent/ID30131A/en unknown
- 2000-02-01 HU HU0105019A patent/HUP0105019A3/en unknown
- 2000-02-01 WO PCT/GB2000/000285 patent/WO2000045819A1/en active IP Right Grant
- 2000-02-01 SK SK1111-2001A patent/SK11112001A3/en not_active Application Discontinuation
- 2000-02-01 EP EP00901748A patent/EP1150679A1/en not_active Withdrawn
- 2000-02-01 NZ NZ512681A patent/NZ512681A/en not_active IP Right Cessation
- 2000-02-01 BR BR0007991-0A patent/BR0007991A/en not_active Application Discontinuation
- 2000-02-01 AU AU23051/00A patent/AU769897B2/en not_active Revoked
- 2000-02-01 CA CA002358641A patent/CA2358641A1/en not_active Abandoned
- 2000-02-04 MY MYPI20000415A patent/MY136382A/en unknown
-
2001
- 2001-07-10 IS IS5996A patent/IS5996A/en unknown
- 2001-08-03 NO NO20013810A patent/NO319827B1/en active IP Right Review Request
-
2002
- 2002-04-10 HK HK02102713.0A patent/HK1040924A1/en unknown
-
2011
- 2011-02-22 JP JP2011035406A patent/JP2011137023A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ID30131A (en) | 2001-11-08 |
| CZ20012631A3 (en) | 2001-10-17 |
| JP2002536333A (en) | 2002-10-29 |
| NZ512681A (en) | 2003-12-19 |
| HK1040924A1 (en) | 2002-06-28 |
| EE04659B1 (en) | 2006-08-15 |
| KR20010089631A (en) | 2001-10-06 |
| AU769897B2 (en) | 2004-02-05 |
| NO20013810D0 (en) | 2001-08-03 |
| HUP0105019A2 (en) | 2002-05-29 |
| AR022462A1 (en) | 2002-09-04 |
| JP2011137023A (en) | 2011-07-14 |
| CA2358641A1 (en) | 2000-08-10 |
| IL144662A0 (en) | 2002-05-23 |
| IS5996A (en) | 2001-07-10 |
| MY136382A (en) | 2008-09-30 |
| HUP0105019A3 (en) | 2003-02-28 |
| TR200102236T2 (en) | 2001-12-21 |
| NO20013810L (en) | 2001-10-03 |
| AU2305100A (en) | 2000-08-25 |
| EP1150679A1 (en) | 2001-11-07 |
| NO319827B1 (en) | 2005-09-19 |
| CN1347320A (en) | 2002-05-01 |
| EE200100404A (en) | 2002-10-15 |
| WO2000045819A1 (en) | 2000-08-10 |
| KR100699287B1 (en) | 2007-03-26 |
| PL349137A1 (en) | 2002-07-01 |
| SK11112001A3 (en) | 2002-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2407532C9 (en) | Combinations for treatment of diseases including cell proliferation | |
| CR10114A (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE INHIBITORS OF HMG COA REDUCTASA (DIVISIONAL OF EXP. 6687) | |
| BR0108435A (en) | Formulation and use of low dose entecavir | |
| CY1109756T1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING Crystalline Salts 7- [4- (4-Fluorophenyl) -6-Isopropyl-2- [Methyl (Methylsulfonyl) -5-5-yl] -3-5-amino-3-yl] -5-y -NIGHT ACID | |
| BRPI0511532A (en) | compound, use thereof, pharmaceutical composition, and, methods for the therapy of functional gastrointestinal disorders and irritable bowel syndrome in a warm-blooded animal, and for the preparation of a compound | |
| BR0114610A (en) | Compound Usage and Pharmaceutical Composition | |
| HUP0302319A2 (en) | Pharmaceutical compositions for the oral delivery of pharmacologically active agents | |
| BR0316050A (en) | Methods of treating, controlling or preventing specific cancer and disease associated with unwanted angiogenesis and reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy, or immunotherapy in a patient. suffering from a specific cancer, pharmaceutical composition and kit | |
| BR0214806A (en) | 5,7,14-triazatetracyclo- {10.3.1.02,11.0,4,9] -hexadeca-2 (11), 3,5,7,9-pentene pharmaceutical compositions | |
| DE69940557D1 (en) | A HYDROCOLLOID AND A DELIVERY-RELATED TABLET CONTAINING CELLULOSE ETHER | |
| BRPI0008228B8 (en) | pharmaceutical composition containing n-benzoyl staurosporine and solubilizing agents | |
| BRPI0515860B8 (en) | tetralin and indane derivatives, their uses, and pharmaceutical composition | |
| JP2006508953A5 (en) | ||
| NO20063277L (en) | Pharmaceutical composition of vinflunine intended for parenteral administration, preparation and use thereof | |
| DK1383752T3 (en) | Deuterated 3-piperidinopropiophenones as well as drugs containing these compounds | |
| BR0013009A (en) | Use of cgrp antagonists and cgrp release inhibitors to combat menopausal hot jets | |
| BR0007991A (en) | Use of the compound (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] - (3r, 5s) -3,5-dihydroxiept -6-enoic, or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods of preparing a pharmaceutical composition, reducing the levels of c-ldl and the lipid ratio of c-ldl / c-hdl, and, regimen dosage | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| FR2699176B1 (en) | New bicyclic pyrimidine compounds, process for their preparation and pharmaceutical compositions containing them. | |
| TR200200913T2 (en) | Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog. | |
| RU2005131839A (en) | MEANS, POTENTIATING ANTITUMINAL EFFECT, AND ANTITUMRIC AGENT | |
| BRPI0415651A (en) | methods for treating, preventing, modifying and / or administering fibromyalgia, and for reducing or preventing an adverse effect associated with the administration of a second active ingredient in a fibromyalgia patient, and, pharmaceutical composition. | |
| JP2002536333A5 (en) | ||
| BRPI0412453A (en) | ascorbic acid or a physiologically acceptable salt thereof | |
| WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O, 11, 13 E 25 DA LPI. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |